Protection by Panax ginseng C.A. Meyer against the genotoxicity of doxorubicin in somatic cells of Drosophila melanogaster

Panax ginseng is one of the most widely prescribed herbal medicines for the treatment of cancer, diabetes, chronic inflammation, and neurodegenerative and cardiovascular diseases. Since the use of alternative medicines in combination with conventional therapy may increase the risk of unwanted interactions, we investigated the possible genotoxicity of a water-soluble form of the dry root of P. ginseng (2.5, 5.0 or 10.0 mg/mL) and its ability to protect against the genotoxicity of doxorubicin (DOX; 0.125 mg/mL) by using the Drosophila melanogaster wing somatic mutation and recombination test (SMART) with standard and high-bioactivation crosses of flies. Panax ginseng was not genotoxic at the concentrations tested, whereas DOX-induced genotoxicity in marker-heterozygous flies resulted mainly from mitotic recombination. At low concentrations, P. ginseng had antirecombinogenic activity that was independent of the concentration of extract used. Recombination events may promote cancer, but little is known about the ability of P. ginseng to inhibit such recombination or modulate DNA repair mechanisms.

Cytogenetic effects of mebendazole on in vivo and in vitro mammalian systems

Mebendazole (MBZ), (methyl-5 benzoyl benzimidazole-2-carbamate), a potent antihelmintic agent, was tested for clastogenicity in Wistar rat bone marrow cells (l3OO, 1750, 3500 and 7000 mg/kg b.w.) and for both clastogenicity and antimitotic potential in human peripheral blood lymphocytes in culture (5, 10 and 20 mug/ml culture medium). One-hundred metaphases/treatment were analyzed for induction of chromosome aberrations and 2000 cells/treatment were counted to determine the mitotic index. MBZ did not induce an increase in the frequency of chromosome aberrations, however it was effective in blocking the cell cycle at metaphase.